Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H16N6O.2H2O |
Molecular Weight | 356.3791 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.NC(=N)NC(=O)C1=C(C2CC2)N(N=C1)C3=CC=CC4=NC=CC=C34
InChI
InChIKey=QPPWXJDIWWFABW-UHFFFAOYSA-N
InChI=1S/C17H16N6O.2H2O/c18-17(19)22-16(24)12-9-21-23(15(12)10-6-7-10)14-5-1-4-13-11(14)3-2-8-20-13;;/h1-5,8-10H,6-7H2,(H4,18,19,22,24);2*1H2
Molecular Formula | C17H16N6O |
Molecular Weight | 320.3485 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/12595915Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11259552
http://www.abcam.com/zoniporide-hydrochloride-ab142012.html
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12595915
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11259552
http://www.abcam.com/zoniporide-hydrochloride-ab142012.html
Zoniporide hydrochloride is a novel, potent and selective NHE-1 inhibitor (IC50 = 14 nM). Reduces infarct size in the isolated heart (EC50 = 0.25 nM). Attenuates post-ischemic cardiac contractile dysfunction and ischemia-reperfusion-induced ventricular fibrillation in vivo. Zoniporide hydrochloride represents a novel class of potent and selective human NHE-1 inhibitors with potential utility for providing cardioprotection in a clinical setting.
Originator
Sources: http://adisinsight.springer.com/drugs/800018057
Curator's Comment: # Pfizer
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3133 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12595915 |
12000.0 nM [IC50] | ||
Target ID: CHEMBL2781 |
14.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.07 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11277524 |
1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
ZONIPORIDE plasma | Rattus norvegicus population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11277524 |
1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
ZONIPORIDE plasma | Rattus norvegicus population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
46% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11277524 |
1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
ZONIPORIDE plasma | Rattus norvegicus population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
12 mg/kg 1 times / day multiple, intravenous Highest studied dose Dose: 12 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 12 mg/kg, 1 times / day Sources: Page: p.573 |
unhealthy, ADULT n = 266 Health Status: unhealthy Condition: peripheral vascular disease Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 266 Sources: Page: p.573 |
Disc. AE: Hepatic failure, Bilirubin elevated... Other AEs: Headache, Atrial fibrillation... AEs leading to discontinuation/dose reduction: Hepatic failure (0.8%) Other AEs:Bilirubin elevated Vomiting (25.6%) Headache (6.4%) Sources: Page: p.573Atrial fibrillation (6.4%) Tachycardia (10.9%) Jaundice (2.3%) Nausea (41.7%) Elevated liver enzyme levels |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Elevated liver enzyme levels | 12 mg/kg 1 times / day multiple, intravenous Highest studied dose Dose: 12 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 12 mg/kg, 1 times / day Sources: Page: p.573 |
unhealthy, ADULT n = 266 Health Status: unhealthy Condition: peripheral vascular disease Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 266 Sources: Page: p.573 |
|
Hepatic failure | 0.8% Disc. AE |
12 mg/kg 1 times / day multiple, intravenous Highest studied dose Dose: 12 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 12 mg/kg, 1 times / day Sources: Page: p.573 |
unhealthy, ADULT n = 266 Health Status: unhealthy Condition: peripheral vascular disease Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 266 Sources: Page: p.573 |
Tachycardia | 10.9% | 12 mg/kg 1 times / day multiple, intravenous Highest studied dose Dose: 12 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 12 mg/kg, 1 times / day Sources: Page: p.573 |
unhealthy, ADULT n = 266 Health Status: unhealthy Condition: peripheral vascular disease Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 266 Sources: Page: p.573 |
Jaundice | 2.3% | 12 mg/kg 1 times / day multiple, intravenous Highest studied dose Dose: 12 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 12 mg/kg, 1 times / day Sources: Page: p.573 |
unhealthy, ADULT n = 266 Health Status: unhealthy Condition: peripheral vascular disease Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 266 Sources: Page: p.573 |
Vomiting | 25.6% Disc. AE |
12 mg/kg 1 times / day multiple, intravenous Highest studied dose Dose: 12 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 12 mg/kg, 1 times / day Sources: Page: p.573 |
unhealthy, ADULT n = 266 Health Status: unhealthy Condition: peripheral vascular disease Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 266 Sources: Page: p.573 |
Nausea | 41.7% | 12 mg/kg 1 times / day multiple, intravenous Highest studied dose Dose: 12 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 12 mg/kg, 1 times / day Sources: Page: p.573 |
unhealthy, ADULT n = 266 Health Status: unhealthy Condition: peripheral vascular disease Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 266 Sources: Page: p.573 |
Atrial fibrillation | 6.4% | 12 mg/kg 1 times / day multiple, intravenous Highest studied dose Dose: 12 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 12 mg/kg, 1 times / day Sources: Page: p.573 |
unhealthy, ADULT n = 266 Health Status: unhealthy Condition: peripheral vascular disease Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 266 Sources: Page: p.573 |
Headache | 6.4% | 12 mg/kg 1 times / day multiple, intravenous Highest studied dose Dose: 12 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 12 mg/kg, 1 times / day Sources: Page: p.573 |
unhealthy, ADULT n = 266 Health Status: unhealthy Condition: peripheral vascular disease Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 266 Sources: Page: p.573 |
Bilirubin elevated | Disc. AE | 12 mg/kg 1 times / day multiple, intravenous Highest studied dose Dose: 12 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 12 mg/kg, 1 times / day Sources: Page: p.573 |
unhealthy, ADULT n = 266 Health Status: unhealthy Condition: peripheral vascular disease Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 266 Sources: Page: p.573 |
PubMed
Title | Date | PubMed |
---|---|---|
A novel sodium-hydrogen exchanger isoform-1 inhibitor, zoniporide, reduces ischemic myocardial injury in vitro and in vivo. | 2001 Apr |
|
An overview of inhibitors of Na(+)/H(+) exchanger. | 2003 Jun |
|
Basolateral Na+-H+ exchanger-1 in rat taste receptor cells is involved in neural adaptation to acidic stimuli. | 2004 Apr 1 |
|
Cardioprotective efficacy of zoniporide, a potent and selective inhibitor of Na+/H+ exchanger isoform 1, in an experimental model of cardiopulmonary bypass. | 2004 May |
|
Efficacy of zoniporide, an Na/H exchange ion inhibitor, for reducing perioperative cardiovascular events in vascular surgery patients. | 2005 Oct |
|
The rise of [Na(+)] (i) during ischemia and reperfusion in the rat heart-underlying mechanisms. | 2007 Sep |
|
Effects of KR-33028, a novel Na+/H+ exchanger-1 inhibitor, on glutamate-induced neuronal cell death and ischemia-induced cerebral infarct. | 2009 Jan 12 |
|
In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. | 2010 Aug |
|
Role of the spinal Na+/H+ exchanger in formalin-induced nociception. | 2011 Aug 21 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12595915
Rabbits: 0.25, 1, and 4 mg/kg/h, i.v.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12223226
Zoniporide inhibited 22Na(+) uptake in fibroblasts expressing human NHE-1 in a concentration-dependent manner (IC(50) = 14 nM)
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 00:06:20 GMT 2023
by
admin
on
Sat Dec 16 00:06:20 GMT 2023
|
Record UNII |
437RZL4834
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
437RZL4834
Created by
admin on Sat Dec 16 00:06:20 GMT 2023 , Edited by admin on Sat Dec 16 00:06:20 GMT 2023
|
PRIMARY | |||
|
DTXSID30235500
Created by
admin on Sat Dec 16 00:06:20 GMT 2023 , Edited by admin on Sat Dec 16 00:06:20 GMT 2023
|
PRIMARY | |||
|
22267705
Created by
admin on Sat Dec 16 00:06:20 GMT 2023 , Edited by admin on Sat Dec 16 00:06:20 GMT 2023
|
PRIMARY | |||
|
863406-98-8
Created by
admin on Sat Dec 16 00:06:20 GMT 2023 , Edited by admin on Sat Dec 16 00:06:20 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
|